Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2003
11/19/2003CN1127954C Use of R(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4- piperidinemethanol for treatment of sleep disorders
11/19/2003CN1127948C Microencapsulated bovine adrenal medulla chromaffin cell-drug for alleviating pain
11/19/2003CN1127902C Health-care tea for tranquilizing and improving sleep
11/18/2003US6649811 Use of nimesulide for the preparation of a pharmaceutical formulation for treating a neurodegenerative condition
11/18/2003US6649648 Administering 1-chroman, 1-thiochroman or quinoline derivative as anticarcinogenic or antimetastasis agent
11/18/2003US6649640 Isoxazole compositions useful as inhibitors of ERK
11/18/2003US6649636 Cyclooxygenase inhibitors
11/18/2003US6649633 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
11/18/2003US6649629 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
11/18/2003US6649627 N-Substituted with 1- (pyrid-2-yl)-piperidine-4-yl radical; gastrointestinal and psychological disorder treatment; antidiabetic tocolytic, and antidepressant agents; irritable bowel syndrome, glaucoma and dysmenorrhoea
11/18/2003US6649626 Stimulants of gamma -aminobutyric acid receptors; psychological disorders
11/18/2003US6649622 Treating diabetes, especially Type II diabetes
11/18/2003US6649616 For therapy and prophylaxis of cardiovascular disorders caused by ischaemia
11/18/2003US6649611 Potent and selective inhibitors of chemokine binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).
11/18/2003US6649609 Benzimidazole derivatives and pharmaceutical compositions comprising these compounds
11/18/2003US6649607 Compositions and methods for treating or preventing convulsions or seizures
11/18/2003US6649604 Analgesics; antidiabetic agents; antiinflamamtory agents
11/18/2003US6649600 2,6-Dioxo or dithioxy-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo derivatives; highly potent and selective diuretics
11/18/2003US6649589 Blocking tumor necrosis factor activity with soluble cytokine receptor, monoclonal antibody or tetracycline derivative
11/18/2003US6649389 Peptide for use in the diagnosis and treatment of cancer, thyroid, diabetes, atherosclerosis, and cardiovascular disorders
11/18/2003US6649388 Polypeptides derived from JNK3
11/18/2003US6649345 Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders
11/18/2003US6649196 Methods of reducing β-amyloid polypeptides
11/18/2003US6649186 Effervescent granules and methods for their preparation
11/18/2003US6649172 5-(p-carboxybenzyloxy)-2-oxybenzaldehyde derivatives; vaccine adjuvants
11/18/2003US6649160 Sertoli cells as transplantation facilitator for cell transplantation
11/18/2003US6649147 Delivery system for oral care compositions comprising organosiloxane resins using a removable backing strip
11/18/2003CA2127472C New adenosine derivatives, preparation methods and pharmaceutical compositions containing them
11/17/2003CA2429097A1 Composition of solutions for organ protection
11/13/2003WO2003093499A2 Therapeutic use of selective pde10 inhibitors
11/13/2003WO2003093485A2 Optimization of transgene expression in mammalian cells
11/13/2003WO2003093299A2 Insulin-associated peptides with effects on cerebral health
11/13/2003WO2003093273A1 Imidazo-triazine derivatives as ligands for gaba receptors
11/13/2003WO2003093272A1 Imidazo-triazine derivatives as ligands for gaba receptors
11/13/2003WO2003093264A1 Oxadiazole derivatives for inhibition of gamma secretase
11/13/2003WO2003093263A1 Substituted imidazole derivatives: gabaa receptor ligands
11/13/2003WO2003093254A1 Semicarbazide derivatives for combating thromboembolic diseases
11/13/2003WO2003093253A1 Alkynyl-substituted spirocyclic sulfamides for the treatment of alzheimer's disease
11/13/2003WO2003093252A1 Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase
11/13/2003WO2003093251A1 Alkenyl-substituted spirocyclic sulfamides as inhibitors of gamma-secretase
11/13/2003WO2003093249A1 Thiazolidinones and the use thereof as polo-like kinase inhibitors
11/13/2003WO2003093248A1 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
11/13/2003WO2003093245A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists
11/13/2003WO2003093240A1 Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
11/13/2003WO2003093237A1 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
11/13/2003WO2003093236A1 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor
11/13/2003WO2003093235A1 Carboxylic acid amides
11/13/2003WO2003093234A1 Melanocortin receptor ligands
11/13/2003WO2003092790A2 Methods for increasing the therapeutic response to electroconvulsive therapy ('ect')
11/13/2003WO2003092732A1 Ph-sensitive polymer
11/13/2003WO2003092725A1 Method for control of depression using c terminal growth hormone (gh) fragment
11/13/2003WO2003092716A2 Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
11/13/2003WO2003092709A1 Method for producing preparations rich in tocotrienol
11/13/2003WO2003092707A1 Use of xenon for the control of neurological deficits associated with cardiopulmonary bypass
11/13/2003WO2003092706A1 Re-epithelializing pharmaceutical compositions comprising xanthan gum
11/13/2003WO2003092701A2 Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders
11/13/2003WO2003092699A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
11/13/2003WO2003092693A1 Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
11/13/2003WO2003092691A1 Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
11/13/2003WO2003092690A1 N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders
11/13/2003WO2003092689A1 The treatment of pain with ifendropil
11/13/2003WO2003092688A2 Heterocyclic derivatives as opioid modulators
11/13/2003WO2003092686A1 Inhibitors of histone deacetylase
11/13/2003WO2003092684A1 TIME-RESOLVED FLUORESCENCE ASSAY FOR THE DETECTION OF MULTIMERIC FORMS OF A-β[BETA] OR OTHER AGGREGATING POLYPEPTIDES
11/13/2003WO2003092681A1 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-[1,2,4]-triazole for the treatment of autoimmune diseases
11/13/2003WO2003092678A1 1-substituted imidazole derivatives as nos inhibitors
11/13/2003WO2003092677A1 Trans-epicutaneous administration form for treating restless leg syndrome
11/13/2003WO2003092675A1 Drugs for mitigating taxane-induced neurotoxicity
11/13/2003WO2003092670A1 Bombesin antagonists
11/13/2003WO2003092660A1 Monocompartment osmotic controlled drug delivery system
11/13/2003WO2003092648A1 Methods and dosage forms for controlled delivery of oxycodone
11/13/2003WO2003092624A2 Use of heat shock proteins to enhance efficacy of antibody therapeutics
11/13/2003WO2003092613A2 Catechin multimers as therapeutic drug delivery agents
11/13/2003WO2003092608A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof
11/13/2003WO2003092605A2 Protease inhibitors
11/13/2003WO2003092599A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
11/13/2003WO2003092588A2 4-azasteroid derivatives as androgen receptor modulators
11/13/2003WO2003092580A2 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
11/13/2003WO2003080617A8 Pyrazolopyrimidine derivatives
11/13/2003WO2003076417A3 Oxo-azabicyclic compounds
11/13/2003WO2003072090A3 Use of tyrosine kinase inhibitors for treating cns disorders
11/13/2003WO2003066621A8 Piperidine derivatives and their use as antagonists of tachykinins
11/13/2003WO2003064447A3 Immune-modulating peptide
11/13/2003WO2003057688A3 Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators
11/13/2003WO2003057672A3 Tetrahydroquinoline analogues as muscarinic agonists
11/13/2003WO2003057165A3 COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
11/13/2003WO2003042113A8 Production of cell suspensions
11/13/2003WO2003041563A3 Neurotransmitter balance chemotherapy
11/13/2003WO2003032897A3 Azabicyclic compounds for the treatment of fibromyalgia syndrome
11/13/2003WO2003031459A3 Modulation of the expression of genes dependent on stat-1
11/13/2003WO2003031407A3 β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
11/13/2003WO2003030944A3 Inhibition of stat-1
11/13/2003WO2003029221A8 Tetrahydroisochinolines, their production and the use thereof as analgesics
11/13/2003WO2003029200A3 Compounds useful as reversible inhibitors of cysteine proteases
11/13/2003WO2003028727A9 3-`hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors
11/13/2003WO2003022360A3 Thermotherapy via targeted delivery of nanoscale magnetic particles
11/13/2003WO2003018134A3 Bioadhesive compositions and methods for enhanced mucosal drug absorption
11/13/2003WO2003015780A3 Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
11/13/2003WO2003013432A3 Methods of use for novel sulfur containing organic nitrate compounds
11/13/2003WO2003012111A3 Conjugates for the modulation of immune responses
1 ... 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 ... 1833